Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Competition that drives down the cost of Wegovy and Zepbound could help employers' health plans offer the drugs to more plan participants and improve the participants' health without causing ...

Here are reactions to the news from analysts and investors in alphabetical order by company name ... on the Novo Nordisk Board of Directors for election in 2026. The changes are without any ...

but without a meaningful change in its near-term strategy, the company's path forward seems difficult. DANSKE BANK ANALYST CARSTEN LONBORG MADSEN "The way we know Novo Nordisk is that normally you ...

"Adding Novo Nordisk's FDA-approved treatments at the best available cash price will help more patients nationwide get the obesity care they need to achieve their goals, particularly those without ...

according to manufacturer Novo Nordisk. The drugmaker announced Tuesday it had reached an agreement with telehealth groups Hims & Hers, Ro and LifeMD to sell name-brand Wegovy at reduced prices, which ...

The companies announced Tuesday that brand-name Wegovy ... list price without insurance is about $1,086. In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh ...

But now that supplies have recovered, brand-name companies are pressing federal ... Ozempic injection pens are seen on the production line at a Novo Nordisk factory in Hillerod, Denmark, on ...

Novo Nordisk scored a huge legal victory that largely ... pharmacists can legally make compounded versions of brand-name medications. Many telehealth companies, such as Hims & Hers, also offered ...

They’re sort of like alternatives when the patient can’t take the brand name.” People may consider ... usage “can be risky for patients.” Novo Nordisk, the pharmaceutical giant that ...